Assessment of Cytotoxic Effects of Quercetin Nanoemulgel on Different Skin Cancer cell lines.

IF 2.4 4区医学 Q3 CHEMISTRY, MEDICINAL

Drug Development and Industrial Pharmacy Pub Date : 2025-06-04 DOI:10.1080/03639045.2025.2509274

Joshna Booravilli, Janaki Devi Sirisolla

{"title":"Assessment of Cytotoxic Effects of Quercetin Nanoemulgel on Different Skin Cancer cell lines.","authors":"Joshna Booravilli, Janaki Devi Sirisolla","doi":"10.1080/03639045.2025.2509274","DOIUrl":null,"url":null,"abstract":"Objective: Quercetin, a polyphenolic flavonoid with antioxidant and anticancer effects, has limited use due to poor water solubility. The objective of this study was to improve the therapeutic effectiveness of quercetin by developing a topical quercetin nanoemulgel.Method: By optimizing the oil (clove oil) and smix ratio (Tween 20:propylene glycol), quercetin nanoemulsion was prepared by spontaneous emulsification method and then evaluated. The optimized nanoemulsion was further prepared to form quercetin nanoemulgel.Results: According to evaluation studies, the optimized quercetin nanoemulsion (QUE NE 3) exhibited stability with a negative zeta potential (-38.2 mV), a tiny particle size (98.2 nm), and high entrapment effectiveness (96.36%). The optimized nanoemulsion was formulated into a nanoemulgel (QUE NEG 3). Studies on ex vivo drug release of quercetin nanoemulgel (QUE NEG 3) showed improved permeability, with cumulative drug release of 93.56 ± 1.16% in 8 h, which was greater than standard quercetin gel (QG) and drug free loaded nanoemulgel (DFL NEG). This was proved by CLSM which shows the delivery of QUE NEG 3 into the dermis. Dose-dependent inhibitory effects were found in cytotoxicity assays conducted on skin cancer cell lines (TE 354.T, A431, and A375) by using the MTT assay. The results demonstrated that quercetin nanoemulgel (QUE NEG 3) showed higher cytotoxicity of 66.52% especially against A431 cells. Hence proving its ability to treat squamous cell carcinoma.Conclusion: These findings imply that the quercetin nanoemulgel is a viable drug delivery method for enhancing quercetin's solubility and therapeutic efficacy.","PeriodicalId":11263,"journal":{"name":"Drug Development and Industrial Pharmacy","volume":" ","pages":"1-15"},"PeriodicalIF":2.4000,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Development and Industrial Pharmacy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/03639045.2025.2509274","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Quercetin, a polyphenolic flavonoid with antioxidant and anticancer effects, has limited use due to poor water solubility. The objective of this study was to improve the therapeutic effectiveness of quercetin by developing a topical quercetin nanoemulgel.

Method: By optimizing the oil (clove oil) and smix ratio (Tween 20:propylene glycol), quercetin nanoemulsion was prepared by spontaneous emulsification method and then evaluated. The optimized nanoemulsion was further prepared to form quercetin nanoemulgel.

Results: According to evaluation studies, the optimized quercetin nanoemulsion (QUE NE 3) exhibited stability with a negative zeta potential (-38.2 mV), a tiny particle size (98.2 nm), and high entrapment effectiveness (96.36%). The optimized nanoemulsion was formulated into a nanoemulgel (QUE NEG 3). Studies on ex vivo drug release of quercetin nanoemulgel (QUE NEG 3) showed improved permeability, with cumulative drug release of 93.56 ± 1.16% in 8 h, which was greater than standard quercetin gel (QG) and drug free loaded nanoemulgel (DFL NEG). This was proved by CLSM which shows the delivery of QUE NEG 3 into the dermis. Dose-dependent inhibitory effects were found in cytotoxicity assays conducted on skin cancer cell lines (TE 354.T, A431, and A375) by using the MTT assay. The results demonstrated that quercetin nanoemulgel (QUE NEG 3) showed higher cytotoxicity of 66.52% especially against A431 cells. Hence proving its ability to treat squamous cell carcinoma.

Conclusion: These findings imply that the quercetin nanoemulgel is a viable drug delivery method for enhancing quercetin's solubility and therapeutic efficacy.

查看原文本刊更多论文

槲皮素纳米凝胶对不同皮肤癌细胞系细胞毒作用的研究。

槲皮素是一种具有抗氧化和抗癌作用的多酚类黄酮，但由于其水溶性较差，限制了其应用。本研究的目的是通过研制一种外用槲皮素纳米凝胶来提高槲皮素的治疗效果。方法：通过优化精油（丁香油）和混合比例（吐温20：丙二醇），采用自发乳化法制备槲皮素纳米乳，并对其进行评价。进一步制备优化后的纳米乳，形成槲皮素纳米乳。结果：评价研究表明，优化后的槲皮素纳米乳（QUE NE 3）具有良好的稳定性，具有负zeta电位（-38.2 mV），粒径小（98.2 nm），包封率高（96.36%）。将优化后的纳米乳液配制成QUE NEG 3纳米乳液。槲皮素纳米凝胶（QUE NEG 3）的体外释药研究显示，槲皮素纳米凝胶（QUE NEG 3）的体外释药通透性得到改善，8 h内累积释药率为93.56±1.16%，高于标准槲皮素凝胶（QG）和无药纳米凝胶（DFL NEG）。CLSM证实了这一点，显示QUE NEG 3进入真皮层。在对皮肤癌细胞系（te354）进行的细胞毒性试验中发现了剂量依赖的抑制作用。T， A431和A375)。结果表明，槲皮素纳米乳（QUE NEG 3）对A431细胞的细胞毒性高达66.52%。从而证明了其治疗鳞状细胞癌的能力。结论：槲皮素纳米凝胶是提高槲皮素溶解度、提高槲皮素治疗效果的一种可行的给药方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Drug Development and Industrial Pharmacy 医学-药学

CiteScore

6.80

自引率

0.00%

发文量

审稿时长

4.5 months

期刊介绍： The aim of Drug Development and Industrial Pharmacy is to publish novel, original, peer-reviewed research manuscripts within relevant topics and research methods related to pharmaceutical research and development, and industrial pharmacy. Research papers must be hypothesis driven and emphasize innovative breakthrough topics in pharmaceutics and drug delivery. The journal will also consider timely critical review papers.